title: Establishment and characterization of a cell line, MCO-Y4, derived from canine mammary gland osteosarcoma.
abstract: A cell line, MCO-Y4, was established from a mammary gland osteosarcoma of a 16-year-old female mongrel dog. Histopathologically the tumor was composed of osteoblastic cells with an osteoid meshwork and chondroid matrix. The mean doubling time of the cells at the 93rd passage was 32.39+/-4.66 hr. Immunohistochemically, the osteoblastic and chondroblastic cells were positive for bone morphogenetic protein (BMP)-2/4 and BMP receptor (BMPR) II. The cultured cells were spindle in shape during the growth and the confluent phases. No tumor matrix was detected in the culture dish by alcian blue staining or von-Kossa silver impregnation. MCO-Y4 cells on the chamber slides showed intense immunoreactivity for BMP-2/4 and BMPR II. Noggin, an antagonist for BMP-2/4, showed the growth inhibition on MCO-Y4 cells. In addition, fibronectin might be potential for stimulating growth of MCO-Y4 cells. When transplanted into severe combined immunodeficiency mice, the cells formed tumors consisting of solid proliferation of osteoblastic and fibroblastic cells with woven-bone trabeculae. These tumor cells were intensely positive for BMP-2/4 and BMPR II. Our results suggested that the cell line might be useful for studying the role of BMPs in canine osteosarcoma and the mechanism of ossification.
authors.affiliation: Department of Pathogenetic Veterinary Science, The United Graduate School of Veterinary Science, Yamaguchi University, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kawabata
authors.forename: Kaori
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Nguyen Thi
authors.initials: NT
authors.lastname: Lan
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Uchida
authors.forename: Ryoji
authors.initials: R
authors.lastname: Yamaguchi
authors.forename: Tosiharu
authors.initials: T
authors.lastname: Hayashi
authors.forename: Susumu
authors.initials: S
authors.lastname: Tateyama
mesh_terms: D000818:Animals; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000037:antagonists & inhibitors / Q000378:metabolism; D019485:Bone Morphogenetic Proteins / Q000378:metabolism; D002352:Carrier Proteins / Q000494:pharmacology; D045744:Cell Line, Tumor / Q000166:cytology / Q000473:pathology* / Q000648:ultrastructure; D049109:Cell Proliferation / Q000187:drug effects; D004283:Dog Diseases / Q000473:pathology*; D004285:Dogs; D005260:Female; D007150:Immunohistochemistry / Q000662:veterinary; D015674:Mammary Neoplasms, Animal / Q000473:pathology*; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D012516:Osteosarcoma / Q000473:pathology / Q000662:veterinary*; D014183:Transplantation, Heterologous / Q000662:veterinary; D000099176:Noggin Protein
chemical_list: D052006:Bone Morphogenetic Protein Receptors, Type II; D019485:Bone Morphogenetic Proteins; D002352:Carrier Proteins; D000099176:Noggin Protein